Cosmos Health Inc. reported financial results for the first quarter ended March 31, 2025, highlighting significant improvements in several areas. The company recorded a net loss of $0.82 million, a 56.17% reduction from the $1.87 million loss in the prior-year period, primarily due to costs associated with its Nasdaq U.S. listing. On an adjusted basis, Cosmos Health achieved profitability with Adjusted EBITDA rising by 157.8% to $0.37 million, compared to a loss of $0.64 million in Q1 2024. Adjusted Net Income improved by 139.4% to $0.28 million from a loss of $0.71 million a year earlier. Gross profit increased by 54% to $2.05 million. Revenue was reported at $13.71 million, down from $14.58 million in the previous year. The company's strong performance was attributed to improved gross profitability and disciplined cost management, driven by the wholesale logistics segment CosmoFarm and its nutraceutical and pharmaceutical products portfolio, including Sky Premium Life. Additionally, operating cash burn improved by 94.5%, decreasing to negative $0.19 million from negative $3.41 million in Q1 2024, reflecting better working capital management. Cosmos Health is also expanding its high-margin contract manufacturing segment and growing its C-Scrub antiseptics line, particularly in the UK market. CEO Greg Siokas expressed confidence in the company's strategy and long-term growth potential, as evidenced by his personal investment in Cosmos Health shares. Total stockholders' and mezzanine equity increased by 5.8% to $25.95 million as of March 31, 2025.